zm 241385 has been researched along with cyclopentane in 1 studies
| Studies (zm 241385) | Trials (zm 241385) | Recent Studies (post-2010) (zm 241385) | Studies (cyclopentane) | Trials (cyclopentane) | Recent Studies (post-2010) (cyclopentane) |
|---|---|---|---|---|---|
| 401 | 3 | 124 | 10,498 | 86 | 5,283 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaimovitz, C; Douvdevani, A; Eini, H; Frishman, V; Kachko, L; Lewis, EC; Yulzari, R | 1 |
1 other study(ies) available for zm 241385 and cyclopentane
| Article | Year |
|---|---|
Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Cell Line, Tumor; Cyclopentanes; Fibrosarcoma; Mice; Mice, Knockout; Neoplasms, Experimental; Receptor, Adenosine A2A; Triazines; Triazoles | 2015 |